Arcellx (ACLX) to Release Earnings on Thursday

Key Points

• Arcellx (ACLX) is set to release its Q2 2025 earnings results on August 14, with analysts anticipating a loss of $1.03 per share.
• The company's last earnings report showed a loss of $1.13 per share, missing analyst estimates, alongside a revenue of only $8.13 million compared to predictions of $19.51 million.
• Arcellx has recently attracted institutional investors, with 96.03% of its stock currently owned by these entities, indicating strong interest in the company.

Arcellx (NASDAQ:ACLX - Get Free Report) is anticipated to announce its Q2 2025 earnings results before the market opens on Thursday, August 7th. Analysts expect the company to announce earnings of ($1.03) per share and revenue of $16.76 million for the quarter.

Arcellx (NASDAQ:ACLX - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.94) EPS for the quarter, beating the consensus estimate of ($1.03) by $0.09. The business had revenue of $7.55 million for the quarter, compared to analyst estimates of $16.76 million. Arcellx had a negative return on equity of 41.63% and a negative net margin of 329.93%. On average, analysts expect Arcellx to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Arcellx Trading Down 0.9%

ACLX stock traded down $0.65 during trading on Friday, hitting $70.50. The company had a trading volume of 867,672 shares, compared to its average volume of 446,817. The company has a fifty day moving average price of $67.52 and a two-hundred day moving average price of $65.20. The company has a market cap of $3.89 billion, a P/E ratio of -20.61 and a beta of 0.28. Arcellx has a fifty-two week low of $47.86 and a fifty-two week high of $107.37.

Insider Buying and Selling

In related news, Director Kavita Patel sold 1,500 shares of the company's stock in a transaction dated Tuesday, June 10th. The stock was sold at an average price of $67.36, for a total value of $101,040.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 8.35% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Intech Investment Management LLC boosted its position in shares of Arcellx by 27.7% during the first quarter. Intech Investment Management LLC now owns 21,967 shares of the company's stock worth $1,441,000 after buying an additional 4,760 shares during the period. Empowered Funds LLC acquired a new position in Arcellx during the first quarter valued at approximately $1,768,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Arcellx by 5.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,753 shares of the company's stock valued at $1,893,000 after purchasing an additional 1,390 shares during the last quarter. 96.03% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on ACLX. Citigroup began coverage on Arcellx in a research report on Tuesday, June 17th. They issued a "buy" rating and a $110.00 price objective for the company. Cantor Fitzgerald upgraded Arcellx to a "strong-buy" rating in a research report on Monday, August 4th. Scotiabank boosted their target price on Arcellx from $93.00 to $133.00 and gave the stock a "sector outperform" rating in a research report on Thursday, July 31st. Finally, HC Wainwright restated a "buy" rating and set a $115.00 target price on shares of Arcellx in a research report on Monday, June 16th. Thirteen equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, Arcellx presently has a consensus rating of "Buy" and a consensus target price of $114.31.

Arcellx Company Profile

Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).